RT @K_A_N_E_N_A_S: @ALICIA56483057 Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors https:/…
@ALICIA56483057 Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors https://t.co/UlNZbtJ87S
@TCovid1984 Six months after receiving their second dose of the Pfizer-BioNTech COVID-19 vaccine, people diagnosed with solid tumor cancers had about the same antibody levels as people who hadn’t been diagnosed with cancer, according to a study. https://t.
@tiderium007 @CTVNews https://t.co/dFkdqkHRCz I sincerely hope you don’t die before your time is up. God bless
@BrawndoTheBrave @nadhimzahawi RNA isn't DNA and cannot genetically alter you? I'm shocked I tell you. 🤯 https://t.co/aV3NGXmuUY
@DoctorsManitoba @um_mchp @inky_mark @WinnipegNews any Mb stats/stories?
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
RT @MDinCanada: Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusion…
Covid Pfizer-BNT vaccine safety study in cancer patients, Israel 2021. https://t.co/mTdsq2iN9q Problematic study exclusions. No data anywhere in paper re 17 patients who died? https://t.co/JJPwLkdlaY
@loulou2745 @MistyGaltees @julien_hoang Une étude israélienne a été menée du 15 janvier au 14 mars 2021. Ceci correspond à ce que mon oncologue m’indiquait en février quand elle me l’a proposée et qu’il n’y avait pas beaucoup de données. https://t.co/v9BTR
@BorisVassiliev @MikiLaMalice Bah non elle est hyper à risque https://t.co/7MeL7Ewvtx
@Ciaobella12321 @MikiLaMalice L'étude n'était pas que sur les cancers du sein --> https://t.co/6u3pIiXICq Le cancer n'est pas une contre indication sauf si le médecin l'indique, dans ce cas on a un document certifiant qu'on est pas éligible, et on a pas
RT @SyedAAhmad5: Immunomodulation due to anticancer treatments may affect immunity and immunogenicity of patients with cancer to the BNT162…
RT @SyedAAhmad5: Immunomodulation due to anticancer treatments may affect immunity and immunogenicity of patients with cancer to the BNT162…
Immunomodulation due to anticancer treatments may affect immunity and immunogenicity of patients with cancer to the BNT162b2 vaccine over time. @CD_AACR @UCHealthNews @SWOG https://t.co/pB9CwwcRt0
RT @dhjutsw1: ICYMI: Efficacy & toxicity profile of BNT162b2 vaccine in cancer pts. @UTSWIMchief @UTSWInfDis @UTSWInternalMed @TimothyJBrow…
ICYMI: Efficacy & toxicity profile of BNT162b2 vaccine in cancer pts. @UTSWIMchief @UTSWInfDis @UTSWInternalMed @TimothyJBrownMD @guptaarjun90 @trile1988 @DinoKazi https://t.co/TqiZ4832Kq
RT @CD_AACR: ICYMI: #OnlineFirst— Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. @Ramb…
RT @CD_AACR: ICYMI: #OnlineFirst— Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. @Ramb…
ICYMI: #OnlineFirst— Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. @RambamHCC @ben_irit @TechnionLive #COVID19 https://t.co/X8n4juO33O https://t.co/P9rt4FEte4
RT @CD_AACR: #OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x…
"The majority of patients (84%, n -129) had metastatic disease. The most common cancers were gastrointestinal (36%, n-56), lung (23%, n-36), breast (17%, n-26), and genitourinary (11%, n -18)....."
#Cancers open access: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors | Cancer Discovery https://t.co/HFwBaZvvwd
RT @KathVenango: New study published in @CD_AACR today. Learn more here: https://t.co/hI2Tse4u7X
RT @CD_AACR: #OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x…
RT @CD_AACR: #OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x…
RT @CD_AACR: #OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x…
New study published in @CD_AACR today. Learn more here: https://t.co/hI2Tse4u7X
RT @CD_AACR: #OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x…
👇 One of the first studies to look at long-term (6mo) efficacy of #COVID19 vaccination in patients with solid tumors @ben_irit @RambamHCC @TechnionLive
RT @CD_AACR: #OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x…
#OnlineFirst: Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. https://t.co/x8Xh79pe0C @RambamHCC @ben_irit @TechnionLive #COVID19 https://t.co/srXDst432p